Overview

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis
Phase:
Phase 2
Details
Lead Sponsor:
Pliant Therapeutics, Inc.